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KEY POINTS
 The incidence and prevalence of childhood urolithiasis has been increasing over the last
decade.
 The majority of renal calculi in children are comprised of either calcium oxalate or calcium
phosphate and are often associated with a metabolic abnormality.
 Idiopathic hypercalciuria and hypocitraturia are the most frequently reported metabolic
abnormalities.
 Given the high risk of recurrences in children with idiopathic hypercalciuria and hypocitra-
turia and the importance of excluding rare but treatable conditions such as primary hyper-
oxaluria and cystinuria a comprehensive metabolic evaluation is indicated in all children.INTRODUCTION
Urolithiasis is a fairly common disease in adults with an estimated prevalence of 3% to
5%.1 In economically developed countries, urolithiasis has been regarded as an
uncommon condition in children. The estimated incidence in the United States from
the 1950s to the 1970s is approximately 1% to 2% that of adults.2,3More recent studies
from theUnited States suggest an increase in the incidence andprevalence,4,5 with one
study demonstrating a nearly 5-fold increase in the incidence in the last decade.4
Reports regarding gender predisposition have varied, with some studies suggesting
equal prevalence and others indicating a greater risk among boys.6 Race and geog-
raphy seem to play a vital role in the prevalence and cause of pediatric stone disease.
In certain regions, such as Southeast Asia, the Middle East, India, and Pakistan, calculi
are endemic. Calculi are particularly uncommon in children of African descent. The
endemic calculi observed in developing nations are often confined to the bladder and
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seems to be more common in Caucasian children from the Southeastern region.
Over the last 3 decades the cause of childhood urolithiasis in the United Kingdom
has shifted from predominantly infectious to metabolic in nature.7 Most calculi in the
United States are found in the kidneys or ureters, comprise either calcium oxalate or
calcium phosphate, and often associated with a metabolic abnormality.8PATHOPHYSIOLOGY
Urolithiasis is associated with an identifiable metabolic abnormality in approximately
40% to 50%of children.7–10 Themajormetabolic abnormalities include: hypercalciuria,
hyperoxaluria, hypocitraturia, cystinuria, and hyperuricosuria. Hypercalciuria or hypo-
citraturia are the most frequently reported abnormalities in children.4,7 In the United
States approximately 40% to 65% of calculi comprises calcium oxalate, 14% to 30%
of calcium phosphate, 10% to 20% of struvite, 5% to 10% of cystine, and 1% to 4%
of uric acid.8,11 Rarely, stones may also comprise xanthine, or 2,8-dihydroxyadenine.
The initiation and growth of calculi requires the supersaturation of certain ions in the
urine. The most important determinants of urine solubility and the likelihood of ion
supersaturation (crystallization) are the total urine volume, the concentration of the
stone-forming ions, the concentration of inhibitors of crystallization, the concentration
of promoters of crystallization, and the urine pH. All types of calculi are less likely to
form in dilute urine. Citrate, magnesium, pyrophosphate, certain glycosaminoglycans,
nephrocalcin, and phytates all act to inhibit crystallization of calcium oxalate and
calcium phosphate. Citrate acts as an inhibitor for the formation of calcium stones
and binds to urinary calcium, thereby forming a soluble complex, which decreases
the availability of free ionic calcium necessary for calcium oxalate or calcium phos-
phate crystallization. Citrate also acts as a direct inhibitor of calcium crystal aggrega-
tion and growth.12,13 Conversely, the presence of uric acid promotes calcium oxalate
crystallization, which exemplifies the process of epitaxy, in which the crystal base of
one material allows the growth of a second mineral that it is in the same crystalline
orientation. Urine pH is important in that certain crystals such as cystine (pH <7.5)
and uric acid (pH <6.0) are more likely to aggregate in acid urine whereas calcium
phosphate (pH >6) is more likely to precipitate in alkaline urine. Calcium oxalate solu-
bility is not appreciably affected by changes in urinary pH within the physiologic range.
Crystals in the urine usually form on the surface of a nidus that allows nucleation,
growth, and aggregation of a stone particle at much lower concentrations than would
be required otherwise. Any source of uroepithelial damage (eg, infection, foreign body,
or Randall plaques) can serve as a nidus. Randall plaques comprise calcium phos-
phate crystals, which originate in the basement membrane in the thin loops of Henle.
As the crystals aggregate they fuse into plaques in the interstitium and finally extrude
through the uroepithelium of the renal papillae. Here they form a nidus and are thought
to be critical in the formation of most cases of idiopathic calcium oxalate calculi. As
a result, calcium oxalate calculi, either as monohydrate (whewellite) or as dihydrate
(weddellite), are often admixed with small amounts of calcium phosphate, which
form the initial nidus of the stone. Stones comprising predominantly calcium phos-
phate (brushite) are less common and seem to originate from plugging of the inner
medullary collecting ducts.14
Genitourinary anomalies (hydronephrosis, duplex ureter, posterior uretheral valves,
and bladder exstrophy) are found in approximately 30% of children with urolithiasis.11
Functional or anatomic obstruction predisposes children to stone formation by
promoting stasis of urine and infection. Only 1% to 5% of children with urologic
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patients with both urologic abnormalities and calculi. To emphasize this point, a study
of 22 children with ureteropelvic junction obstruction and noninfectious calculi demon-
strated that 15 (68%) had at least 1 concomitant metabolic abnormality, with hyper-
calciuria being the most common.16 Although infection is commonly associated with
kidney stones, it is unlikely to be causative of non–struvite calculi. Although an impor-
tant source of calculi in children, struvite stones will not be discussed further in this
review because the only medical therapy centers on appropriate antibiotic treatment.
METABOLIC ABNORMALITIES
Hypercalciuria
Hypercalciuria is found in approximately 30% to 50% of stone-forming children.8,9
Hypercalciuria is not a single entity but a condition associated with many causes
(Box 1). The most common cause in children and adults is idiopathic hypercalciuria.
Idiopathic hypercalciuria is defined as hypercalciuria that occurs in the absence of
hypercalcemia in patients in whom no other cause can be identified. The gene (or
genes) responsible for familial idiopathic hypercalciuria has not been identified, but
appear to be transmitted in an autosomal dominant fashion with incomplete pene-
trance. Approximately 4% of asymptomatic healthy children demonstrate evidence
of idiopathic hypercalciuria,17 and 40% to 50% of those children have a positive family
history of urolithiasis.18 Hypercalciuria is formally defined as calcium excretion of
greater than 4 mg/kg/d in children older than 2 years. In many children, a 24-hour urine
collection is not practical and a urine calcium to creatinine ratio is used to estimate
daily calcium excretion (Table 1). In school-aged children, a calcium to creatinine ratio
of 0.2 mg/mg or less is considered normal, although higher values are reported in
younger children.
When hypercalciuria is observed, several conditions must be excluded before
establishing a diagnosis of idiopathic hypercalciuria. By definition the patient should
be normocalcemic. In patients with hypercalcemic hypercalciuria, the possibility of
hyperparathyroidism and hypervitaminosis D should be investigated and, when clini-
cally indicated, a diagnosis of prolonged immobilization, sarcoidosis, malignancy,
juvenile idiopathic arthritis, corticosteroid excess, adrenal insufficiency or William
syndrome should be considered. Children with hypocalcemic hypercalciuria should
be evaluated for hypoparathyroidism and autosomal, dominant hypocalcemic hyper-
calciuria (gain of function mutation in the calcium-sensing receptor). Although the vast
majority of patients with normocalcemic hypercalciuria will ultimately be diagnosed
with idiopathic hypercalciuria, other associated conditions, such as prematurity,
diuretic exposure (furosemide and acetazolamide), anticonvulsant usage (topiramate
and zonisamide), the ketogenic diet, Dent disease, Bartter syndrome, familial
hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), distal renal
tubular acidosis (dRTA), hereditary hypophosphatemic rickets with hypercalciuria
(HHRH), and possibly medullary sponge kidney should be excluded and considered
during the initial evaluation.
Genetic conditions associated with normocalcemic hypercalciuria
Dent disease is an X-linked inherited condition caused by a mutation in the CLCN5
gene. The condition is characterized by low-molecular-weight proteinuria, nephrocal-
cinosis, hypercalciuria, nephrolithiasis, and chronic kidney disease. The clinical
presentation is often insidious with many patients remaining asymptomatic throughout
childhood; however, signs and symptoms of nephrocalcinosis and hypercalciuria
are not uncommon in childhood. The defect is in proximal tubular function, and
Box 1
Clinical disorders associated with hypercalciuria
Hypercalcemia
Hyperparathyroidism
Hypervitaminosis D
Immobilization
Sarcoidosis
Malignancy
Juvenile idiopathic arthritis
Corticosteroid excess
Adrenal insufficiency
Williams syndrome
Idiopathic hypercalcemia of infancy
Hypocalcemia
Hypoparathyroidism
Autosomal dominant hypocalcemic hypercalciuria
Normocalcemia
Acquired
Prematurity
Furosemide
Topiramate
Ketogenic diet
Genetic
Idiopathic
Dent disease
Bartter syndrome
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis
Primary distal renal tubular acidosis (dRTA)
Hereditary hypophosphatemic rickets with hypercalciuria
Other
Medullary sponge kidney
Secondary dRTA
Glycogen-storage disease type I
Copelovitch884occasionally glucosuria, aminoaciduria, metabolic acidosis, and hypophosphatemia
may all occur as part of an associated partial Fanconi syndrome. In a minority of
patients, the Dent phenotype results from a mutation in theOCRL gene (Dent 2), which
is also involved in the oculocerebrorenal syndrome of Lowe.
Bartter syndrome is an autosomal recessive condition characterized by renal
salt wasting, hypokalemia, metabolic alkalosis, hypercalciuria, and normal serum
Table 1
Normal values for urinary solute excretion
Metabolite Age Random (mg/mg) 24-h (All Ages)
Calcium 0–6 mo
7–12 mo
>24 mo
<0.8
<0.6
<0.21
<4 mg/kg/d
Oxalate 0–6 mo
7–24 mo
2–5 y
5–14 y
>16 y
<0.26
<0.11
<0.08
<0.06
<0.03
<50 mg/1.73 m2
Citrate 0–5 y
>5 y
>0.2–0.42 >180 mg/gm Males, >300 mg/gm Females
Cystine >6 mo <0.075 <50 mg/1.73 m2
Uric acid >2 y 0.56 mg/dL GFRa <815 mg/1.73 m2
a Equation 1: Urine uric acid (mg/dL)  Plasma creatinine (mg/dL)/Urine creatinine (mg/dL).
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polyuria, dehydration, emesis, constipation, and failure to thrive. Severe polyhydram-
nios, prematurity, and occasionally sensorineural deafness are the hallmark features.
Mutations in the SLC12A, KCNJ1, and BSND genes (Bartter syndrome type I, type II,
and type IV, respectively) typically result in severe dysfunction of the thick ascending
limb (TAL) of the loop of Henle in the neonatal period (neonatal Bartter syndrome).
Mutations in the ClCKB gene (Bartter syndrome type III) usually cause milder TAL
dysfunction and often present outside the neonatal period (classic Bartter
syndrome).
FHHNC often presents in childhood with seizures or tetany caused by hypomagne-
semia. Other clinical manifestations include frequent urinary tract infections (UTI),
polyuria, polydipsia, failure to thrive, nephrolithiasis, and progressive renal failure.19
FHHNC is an autosomal recessive condition caused by mutations in either the
CLDN-16 or CLDN-19 genes. Homozygous CLDN-16 or -19 mutations are associated
with impaired tight junction integrity in the TAL, urinary magnesium and calcium
wasting, and resultant hypomagnesemia. Patients usually develop the characteristic
triad of hypomagnesemia, hypercalciuria, and nephrocalcinosis. Profound visual
impairment characterized by macular coloboma, significant myopia, and horizontal
nystagmus can been seen in association with CLDN-19 mutations.20
Primary dRTA is an inherited condition characterized by systemic acidosis as
a result of the inability of the distal tubule to adequately acidify the urine. Failure to
thrive, polyuria, polydipsia, hypercalciuria, hypocitraturia, nephrocalcinosis, renal
calculi, and hypokalemia are common presenting signs in infancy. Primary dRTA
may be a dominant (SLC4A1 gene) or a recessive condition (ATP6V1B1 or ATP6V0A4
genes). The inability to secrete H1 ions from the a-intercalated cells of the distal tubule
is caused by either a defective vacuolar H1-ATPase (ATP6V1B1 or ATP6V0A4 genes)
or a defective Cl/HCO3 anion exchanger-1 (SLC4A1 gene). Sensorineural hearing
loss may be found in patients with ATP6V1B1 mutations.
HHRH is a rare, autosomal recessive disorder caused by mutations in the SLC34A3
gene, resulting in loss-of-function of the type IIc sodium phosphate cotransporters of
the proximal tubule. The decreased renal phosphate reabsorption can result in
profound hypophosphatemia, normocalcemia, rickets, and bone pain. Hypercalciuria
Copelovitch886and nephrolithiasis are also commonly observed and may be the result of a hypophos-
phatemia-induced stimulation of 1,25-dihydroxyvitamin D synthesis. The increased
synthesis purportedly causes increased gastrointestinal absorption of calcium and
excessive urinary calcium losses in the face of normal serum calcium levels.21Hyperoxaluria
Oxalate is an end product of the metabolic pathways for glyoxylate and ascorbic acid
and is primarily excreted by the kidneys. The vast majority (80%–85%) of daily urinary
oxalate excretion is derived from normal metabolic homeostasis, and the remainder
(10%–15%) is from dietary intake. Daily urine oxalate excretion is generally less than
50 mg/d/1.73 m2 of body surface area. The impracticality of performing 24-hour urine
collections in very young patients requires the use of a random urine oxalate to creati-
nine ratio, which can be used to estimate oxalate excretion (see Table 1). Increased
urinary oxalate excretion may be caused by an inherited metabolic disorder (primary
hyperoxaluria [PH]) or, more commonly, as a secondary phenomenon caused by
increased oxalate absorption or excessive intake of oxalate precursors.
PH
PH type I and II are relatively rare, autosomal recessive disorders of endogenous
oxalate production. Overproduction of oxalate by the liver causes excessive urinary
oxalate excretion with resultant nephrocalcinosis and nephrolithiasis. The calcium
oxalate deposition results in progressive renal damage; however, the clinical presen-
tation can vary from end-stage renal failure in the neonate to occasional stone
passage into adulthood. Because of the clinical variability, the diagnosis is often over-
looked and only realized after the loss of a transplanted kidney.22
PH type I is caused by mutations in the AGXT gene, which result in a functional
defect of the hepatic peroxisomal enzyme alanine–glyoxylate aminotransferase
(AGT). The deficit leads to accumulation of glyoxylate, glycolate, and oxalate in the
urine.Pyridoxine is an essential cofactor for proper AGT activity and, rarely, profound
vitamin B6 deficiency can mimic PH type I. PH type II is caused by mutations in the
GRHPR gene with resultant deficient glyoxylate reductase–hydroxypyruvate reduc-
tase enzyme activity. Excessive amounts of oxalate and L-glyceric acid are excreted
by the kidney.23 PH type II is somewhat milder compared with PH type I but is not
benign. Recently, a third variant, PH type III has been described in 8 families with
hyperoxaluria and mutations in the DHDPSL gene.24 The exact mechanism by which
hyperoxaluria occurs in PH type III is yet to be fully elucidated.
Secondary hyperoxaluria
In secondary hyperoxaluria, there is either a dietary exposure to large amounts of
oxalate (or oxalate precursors) or an underlying disorder that causes increased
absorption of dietary oxalic acid from the intestinal tract. Gastrointestinal absorption
varies inversely with dietary calcium intake, and, as a result, calcium-deficient diets
may increase oxalate absorption and hyperoxaluria.25 Oxalate is a byproduct of ascor-
bic acid metabolism, and high doses of vitamin C have also been associated with
hyperoxaluria. Increased dietary absorption is usually characterized by fat malabsorp-
tion or a chronic diarrheal disorder. Among secondary causes of hyperoxaluria, those
attributable to gastrointestinal disease are inflammatory bowel disease, celiac
disease, exocrine pancreatic insufficiency (cystic fibrosis), biliary tract disease, and
small bowel resection or short bowel syndrome. The pathogenesis in these conditions
results from the presence of free fatty acids that bind calcium in the intestinal lumen
resulting in more unbound oxalate, which is free to be absorbed.
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Citrate is normally present in the urine and regulated through a process of both
absorption and metabolism at the level of the proximal tubule. Hypocitraturia is gener-
ally defined as a citrate to creatinine ratio of less than 180 mg/gm in men and less than
300 mg/gm in women on a 24-hour collection (see Table 1). Intracellular acidosis of
the proximal tubule, caused by either metabolic acidosis or hypokalemia results in
an increased citrate absorption in the proximal tubule and resultant hypocitraturia.
As a result, the ketogenic diet, certain medications (topiramate, zonisamide, and acet-
azolamide), dRTA, and chronic diarrhea are commonly associated with hypocitraturia.
Given that an incomplete dRTA can occur in the absence of an overt systemic acidosis
or hypokalemia, the condition can often be overlooked in the face of hypocitraturia if
provocative acid-load testing is not readily available. Despite these known
associations, most cases of hypocitraturia are idiopathic although a diet rich in animal
protein and low in vegetable fiber and potassium seems to promote lower citrate
excretion.26,27
Cystinuria
Cystinuria is an autosomal recessive disorder caused by mutations in either the
SLC3A1 or the SLC7A9 genes, resulting in a disordered amino acid transport in the
proximal tubule,28 Cystinuria is characterized by urinary hyperexcretion of cystine
and the dibasic amino acids lysine, ornithine, and arginine. Normal individuals excrete
less than 50–60 mg of cystine/d/1.73 m2 of body surface area, whereas patients who
are homozygous for cystinuria often excrete greater than 400 mg/d/1.73 m2 of body
surface area.7 Patients typically present with renal colic and urolithiasis in the second
or third decade of life; however, they may present as early as infancy with staghorn
calculi. The poor solubility of cystine in the urine causes precipitation in the collecting
system, which, if left untreated, usually results in recurrent episodes of calculi and
long-term risk for renal failure. Associated UTI’s are common, and combined cystine
and struvite calculi have been observed.29
In cystinuria, the disordered cystine transport primarily results from dysfunction of
the heteromeric amino acid transporter (rBAT/b0,1AT), comprising heavy (rBAT) and
light (b0,1AT) subunits. Cystinuria was originally classified into type I and non–type I
(types II and III) based on the urinary cystine concentration pattern of obligate hetero-
zygotes and the presumed mode of inheritance. Type I follows the classic autosomal
recessive inheritance with heterozygotes showing normal cystine excretion. In
contrast, non–type I (type II and III) heterozygotes demonstrate moderate or high
excretion of urinary cystine. Types II and III differ in that type III homozygotes show
a nearly normal increase in cystine plasma levels after oral cystine administration.30
It is now clear that homozygous mutations in the SLC3A1 gene, which encodes
rBAT is associated with type I cystinuira, and homozygous mutations in the SLC7A9
gene, which encodes b0,1AT accounts for most cases of type II and III. A more recent
classification system has been developed, which designates patients who are homo-
zygous for the SLC3A1 mutations as cystinuria type A, patients who are homozygous
for the SLC7A9 mutations as type B, and those who have a mutation in both the
SLC3A1 and SLC7A9 genes as type AB.31
Hyperuricosuria
Uric acid excretion is greater in children than in adults, with the highest urinary frac-
tional excretion (Fe) found in neonates (Fe 30%–50%) and levels reaching adult values
(Fe 8%–12%) in adolescence.32 Hyperuricosuria is defined as uric acid excretion of
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filtration rate (GFR), relative uric acid excretion is fairly constant after 2 years of age
(see Table 1). In children who are not yet trained to use toilet but older than of 2 years,
hyperuricosuria can be defined as greater than 0.56 mg/dL of GFR on a spot urine
collection. This value may be calculated using Equation 1:
Urine uric acid ðmg=dLÞPlasma creatinineðmg=dLÞ=Urine creatinineðmg=dLÞ (1)
Hyperuricosuria in the setting of low urinary pH is the greatest risk factor for uric acid
stone formation. Hyperuricosuria associated with significant hyperuricemia is usually
associated with inherited disorders of purine metabolism (see section on Inherited disor-
ders of purine metabolism), lymphoproliferative disorders, and polycythemia. Rarely,
a condition known as hereditary renal hypouricemia characterized by low serum uric
acid, hyperuricosuria, nephrolithiasis, and exercise-induced acute renal failure has
been observed. Mutations in either the SLC22A12 or the SLC2A9 genes, both of which
encodeurate transporters expressed in theproximal tubule, are known to becausative.28
Other causes of hyperuricosuria include excessive purine intake (animal protein, ancho-
vies, andmussels), hemolysis, uricosuricmedications (probenecid, salicylates, and losar-
tan), cyanotic congenital heart disease, melamine toxicity, and idiopathic (familial). There
is also a phenomenonprimarily observed in adults called hyperuricosuric calciumoxalate
urolithiasis inwhich hyperuricosuria seems to be the principle contributor to the develop-
ment of calcium oxalate stones with either no or minimal uric acid content (epitaxy).
Inherited disorders of purine metabolism
Phosphoribosyl pyrophosphate synthetase superactivity (PRPSS) is an X-linked condi-
tion caused by mutations in the PRPS1 gene. The overactive PRPSS is associated with
excessive purine production. The subsequent purine degradation results in hyperuri-
cemia, gout, hyperuricosuria, and uric acid nephrolithiasis. Some affected individuals
have neurodevelopmental abnormalities, particularly sensorineural deafness.33
Hypoxanthine-guanine phosphoribosyl transferase (HPRT) deficiency is an X-linked
inborn error of purine metabolism caused by mutations in the HPRT1 gene associated
with overproduction of uric acid. Complete deficiency of HPRT activity is associated
with the Lesch-Nyhan syndrome, characterized by mental retardation, spastic cerebral
palsy, choreoathetosis, uric acid calculi, andself-injuriousbehavior. Childrenwith partial
HPRT deficiency can be phenotypically similar to patients with complete deficiencies or
may have more subtle or mild neurologic symptoms. Renal stones, uric acid nephrop-
athy, renal obstruction, or gout may be the first presenting signs of the disease.28CLINICAL PRESENTATION
The classic adult presentation of acute, severe flank pain, which radiates to the groin is
uncommon in children, particularly in children younger than 5 years. Although adoles-
cents present similarly to adult patients, younger children have varied presentations
including nonspecific pain localized to the abdomen, flank, or pelvis. In infants, symp-
toms of stones may be confused with colic pain. Macroscopic or microscopic hema-
turia can occur in up to 90% of children with urolithiasis.34 Ureteral stones are much
more likely to cause obstruction that leads to pain. Renal stones may be found inci-
dentally and remain present for years without causing symptoms. Approximately
10%of calculi can present with dysuria and urinary frequency and are usually localized
to the lower urinary tract. UTI may also complicate nephrolithiasis, although pyuria
may also be present without bacteriuria or infection. Rarely, a urethral stone can
present with acute urinary obstruction.11,35
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Obtaining a thorough medical history followed by careful examination is essential for
establishing an accurate diagnosis. Information pertaining to a family history of calculi,
hematuria, and renal failure can be essential in identifying those patients at highest risk
for inherited metabolic or genetic conditions (eg, cystinuria, primary hyperoxaluria,
and Dent disease). A focused dietary history with special emphasis on fluid and salt
intake, vitamin (C, D) mineral supplementation, and special diets (eg, ketogenic diet)
is indicated in every patient. Eliciting a detailed medication history with special
emphasis on corticosteroids, diuretics (furosemide and acetazolamide), protease
inhibitors (indinavir), and anticonvulsants (topiramate and zonisamide) can be instruc-
tive. Children with a history of prematurity, urinary tract abnormalities, UTIs, intestinal
malabsorption (eg, Crohn’s disease, bowel resection, and cystic fibrosis), and
prolonged immobility are all at special risk for calculi formation. Detailed physical
examination of the child for dysmorphic features (William syndrome), rickets (Dent
disease and HHRH), tetany (FHHNC and autosomal dominant hypocalcemic hypercal-
ciuria), and gout (HPRT deficiency, PRPSS) can be helpful.
EVALUATION
Imaging
The first step involved in the evaluation of urolithiasis is detection of the calculus. The
sensitivity of plain abdominal radiography in the detection of calculi is approximately
45% to 58%; although many stones are radiopaque, radiography alone is insufficient
in the evaluation of a patient with suspected urolithiasis.36 In addition, calculi
comprising uric acid, cystine, xanthine, or indinavir are usually radiolucent. Ultraso-
nography (US) has the ability to detect 90% of calculi confined to the kidney; however,
the sensitivity for detecting ureteral calculi and smaller calculi (<5 mm) is poor.5 None-
theless, because radiation exposure is not without risk, US remains the initial study of
choice in the assessment of calculi in children. Noncontrast computed tomography
remains the gold standard and is indicated in children with persistent symptoms of
urolithiasis and a nondiagnostic US. In patients with hypercalciuria in whommedullary
sponge kidney is suspected, an intravenous pyelogram can be considered.
Metabolic Investigations
When urinary calculi develop during childhood, the risk of life-long stone formation is
significant, with approximately 16% to 20% having recurrences within 3 to 13
years.10,37 Furthermore, children with an identifiable metabolic abnormality have an
up to 5-fold increased risk of having a recurrence as compared with children with
no identifiable metabolic disorder.10 As a result, all children should undergo a compre-
hensive initial evaluation. Whenever possible, analysis should begin with an infrared
spectroscopy or radiograph diffraction analysis of a passed stone. If a cystine or stru-
vite stone is found, the analysis will be diagnostic.
Serum and urine studies should be obtained in patients in whom stone analysis
could not be performed or for those with either calcium or uric acid-based stones. A
serum creatinine level is essential to evaluate for possible acute kidney injury or chronic
kidney disease. Serum calcium, phosphorous, bicarbonate, magnesium, and uric acid
levels are effective in screening for hypercalcemia- and hypocalcemia-associated
calculi (discussed earlier), hyperuricemia, HHRH, Bartter syndrome, dRTA, and
FHHNC. Unlike in adults, primary hyperparathyroidism is rare in children and an intact
parathyroid hormone level is not an essential part of the initial evaluation unless there is
evidence of hypercalcemia and hypophosphatemia. A 25-hydroxyvitamin D level
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bulin (low-molecular-weight protein) is a useful screening test for Dent disease and
should be considered in men and possibly carrier women if there are recurrent
calcium-based calculi in the setting of proteinuria or a family history of renal failure,
focal segmental glomerulosclerosis, or recurrent calculi.
A 24-hour urine collection should be analyzed for calcium, oxalate, uric acid, sodium,
citrate, creatinine levels, volume, pH, and cystine (cyanide-nitroprusside screening
test). Results must be evaluated with respect to weight, body surface area, and
creatinine level to be properly interpreted in children. Urine creatinine excretion (normal
15–25 mg/kg/d) is useful in assessing the adequacy of the urine collection. Supersatu-
rations for calcium oxalate, calcium phosphate, and uric acid can be calculated from
computer models based on the results of the urine collection. There is ongoing contro-
versy as towhether a single 24-hour urine collection at the time of diagnosis is sufficient
for proper evaluation38 or whether 2 separate collections yield a greater number of
specific diagnoses.39 Several commercial companies, including Litholink,Mission, Dia-
non, and Urocor offer these 24-hour urine stone chemistry profiles. Although less
precise, when children are not yet trained to use toilet, the evaluationmaybe performed
bymeasuring the ratio of calcium, uric acid, citrate, and oxalate levels to creatinine level
in a random urine sample. Repeat urine testing should be performed several weeks to
months after a change in diet or after the initiation of a medication. Microscopic urinal-
ysis for crystalluria is generally not diagnostic unless hexagonal crystals (cystine) or
coffin lid–shaped triple phosphate crystals (struvite) are observed.MEDICAL MANAGEMENT
Acute Management
The first goal of medical management should be directed toward control of the acute
complications. Pain associated with the passage of a stone is often severe and should
be treated promptly with narcotic analgesics (morphine sulfate) and/or nonsteroidal
antiinflammatory drugs (Ketorolac). If the patient is vomiting or unable to drink, paren-
teral hydration should be used to maintain a high urine flow rate. In the absence of oli-
goanuric renal failure or a complete obstruction, an intravenous infusion rate of 1.5 to 2
times maintenance is recommended. Agents that may promote the passage of stones
and reduce symptoms (medical expulsive therapy), such as alpha-adrenergic blockers
(tamsulosin) and calcium-channel blockers (nifedipine), have shown promising
results in adults with distal ureteral calculi.40 Although studies in children are limited,
1 prospective study showed that in children with distal ureteral calculi who were
treated with tamsulosin, there was a greater stone expulsion rate and decreased
time to stone expulsion when compared with controls.41 Urine should be strained
for several days to recover any gravel or calculi passed for analysis. Because UTIs
often present concomitantly in children with calculi, a urine culture should be obtained
and empiric antibiotic therapy initiated if a UTI is suspected.
Preventative Measures
Fluid
Fluid intake is a critical component of stone prevention by effectively reducing the
concentration of lithogenic factors, including calcium, oxalate, uric acid, and cystine.
Although high daily fluid intake reduces the risk of recurrent stone formation,42 the
exact prescription is unknown. Most clinicians recommend intake at least equal to
calculated maintenance rates in children and no less than 2 to 2.5 L in adolescents
and adults. Even higher fluid intake levels (1.5–2 L/m2) may be recommended for
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periods of increased insensible water loss. Regarding fluids other than water, reports
suggest that fluids that increase urinary pH and citrate excretion such as orange juice,
lemonade, and black currant juice, as well as those that increase urinary volume such
as coffee, tea, beer, and wine, reduce the risk of calcium stone formation.43
Conversely, grapefruit juices seem to increase the risk of calcium-based stones.43,44
Whether cola drinks increase lithogenic potential or not remains controversial.43,44
Sodium
The association between sodium intake and calcium stone formation has been
reported but has not been confirmed in all studies.44 Increased sodium intake is
known to promote calciuria by competing for reabsorption at the level of the renal
tubules. A low salt diet corresponding to less than 2 to 3 mEq/kg/d in children or
less than 2.4 g/d in adolescents or adults is generally recommended for patients
with hypercalciuria or calcium-containing stones. A low salt diet may also reduce
urinary cystine excretion in patients with cystinuria.
Calcium
Until recently, higher calcium intake was thought to increase the risk of stone forma-
tion; however, there is substantial evidence now that a higher calcium containing diet
is associated with a reduced risk of stone formation.45 A potential mechanism that
might explain this paradox is that higher calcium intake effectively binds dietary
oxalate in the gut, thereby reducing intestinal absorption and eventual urinary oxalate
excretion. The current recommendation for stone formers is to curtail excess calcium
intake, but calcium restriction is not recommended, in part, because of the long-term
risk of osteoporosis. Excess consumption of vitamin D with or without calcium supple-
ments can also induce excessive urinary calcium excretion.
Animal protein
There is compelling evidence for a role of dietary animal proteins (meat, fish, and
poultry) in calcium oxalate stone formation. The metabolism of sulfur-containing
amino acids in animal meat generates an acid load in the form of sulfuric acid. As
a result, excessive dietary animal protein intake causes increased urinary calcium
excretion and reduced urinary citrate excretion and pH. Vegetable and dairy protein
sources do not seem to carry the same lithogenic potential. The consumption of
excessive amounts of dietary animal protein also results in increased purine intake,
increased uric acid production, and may contribute to both uricosuria and more acidic
urine. In patients with cystinuria, there is little evidence to support the dietary restric-
tion of proteins high in cystine content; however, reducing animal protein intake might
be helpful by increasing urinary pH. Children with calculi are recommended not to eat
excessive amounts of protein but should aim for 100% of the daily recommended
allowance for age to supply adequate substrate for growth and nutrition.
Oxalate
The role of dietary oxalate in stone formation is controversial because only approxi-
mately 10% to 20% of urinary oxalate excretion is derived from the diet. As a precau-
tionary measure, most clinicians recommend limiting dietary oxalate ingestion in
calcium oxalate stone formers who demonstrate evidence of hyperoxaluria. Foods
that contain high levels of oxalate include certain nuts (almonds, peanuts, cashews,
walnuts, and pecans), spinach, soy beans, tofu, rhubarb, beets, sweet potatoes,
wheat bran, okra, parsley, chives, black raspberries, star fruit, green tea, and choco-
late. Vitamin C supplements have been associated with increased risk of calcium
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and therefore, these supplements should be discontinued in calcium oxalate stone
formers with hyperoxaluria.46
Potassium/citrate
Potassium-rich foods such as fruits and vegetables usually contain large amounts of
citrate, which are protective against the formation of calcium oxalate stones. In many
studies, a diet high in potassium is protective against urolithiasis.45 In addition,
a potassium-restricted diet can cause increased urinary calcium excretion and overt
hypokalemia, leading to hypocitraturia. One recent study suggests that chronically
low potassium intake in the absence of overt hypokalemia may also result in low
urinary potassium and citrate levels.47 As a result, a diet containing potassium-rich
fruits and vegetables can theoretically increase urinary citrate excretion directly
because of the citrate content found in those foods and indirectly through the dietary
potassium content.
Others
Magnesium complexes with oxalate and may prevent enteric oxalate absorption as
well as decrease calcium oxalate supersaturation in the urine. In some studies, higher
dietary magnesium has been associated with a lower risk of stone formation in men,46
and supplementation may be helpful in the treatment of children with secondary
hyperoxaluria. Carbohydrate ingestion has been associated with hypercalciuria, and
sucrose ingestion has been found to be associatedwith urolithiasis.45 Phyate, a dietary
factor found in many high fiber-containing foods (cereals, legumes, vegetables, and
nuts), seems to bind calcium avidly and may inhibit the formation of calcium oxalate
stones.
Medications
Pharmacotherapy is recommended for children in whom fluid and dietary therapy is
ineffective in controlling the formation of stones, or for those with primary hyperoxa-
luria, cystinuria, or a known genetic condition associated with normocalcemic hyper-
calciuria (see previous section on Genetic conditions associated with normocalcemic
hypercalciuria).
Diuretics
A thiazide diuretic is often required for children with hypercalciuria who do not
respond to a restricted sodium diet. The usual recommendation is hydrochlorothia-
zide 1 to 2 mg/kg/d (adult 25–100 mg/d). Amiloride can be added for its potassium-
sparing effect as well as for its ability to independently reduce calcium excretion.
Alternatively, potassium citrate could be provided to mitigate the effects of potas-
sium depletion. Thiazide diuretics have also been used in an attempt to reduce
calcium excretion in patients with Dent disease, FHHNC, and PH.
Alkali agents
Treatment with either potassium citrate (2–4 mEq/kg/d, adults 30–90 mEq/d)48 or
potassium-magnesium citrate49 has been shown to reduce the recurrence of calcium
oxalate stone formation in patients with low or normal citrate excretion. Sodium citrate
is generally considered less ideal because it is associated with increased sodium
delivery to the nephron. Treatment is considered safe with only minor gastrointestinal
side effects; however, one potential concern is that over-treatment with alkali may
increase the risk of calcium phosphate stone formation by increasing the urinary pH
to greater than 6.5, thereby decreasing the calcium phosphate supersaturation
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disease, FHHNC, dRTA, uric acid lithiasis (goal of urine pH >6.5), cystinuria (goal of
urine pH >7), and hyperoxaluria.
Thiol-containing agents
These agents are used exclusively for patients with cystinuria in whom fluid and die-
tary modifications as well as urinary alkalinization are ineffective in preventing stone
recurrences or dissolving preexisting stones. The 2 most common agents are D-peni-
cillamine and a-mercaptopropionylglycine (tiopronin). Cystine is formed as a dimer of
cysteine and these agents work by reducing the disulfide bond that bridges the 2
molecules of cysteine. The thiol group combines with cysteine to form a more soluble
cysteine-drug product combination, which is be excreted. D-penicillamine has a large
number of adverse side effects, including febrile reactions, gastrointestinal discom-
fort, liver dysfunction, impaired taste, bone marrow suppression, trace metal defi-
ciencies, membranous glomerulopathy, myasthenia gravis, and skin eruptions
(elastosis perforans serpiginosa). The incidence of adverse effects for a-mercaptopro-
pionylglycine is similar but may be slightly less. Monitoring of liver enzymes, complete
blood count, urinalysis, and copper and zinc levels should be performed regularly.
Special assays (solid-phase assay or high performance liquid chromatography) can
readily distinguish between urinary cystine and cysteine-drug complexes and may
help in guiding long-term medical therapy.
Allopurinol
Themainstay of therapy for most children with uric acid calculi is a combination of high
urine flow rate and alkalinization of the urine. Allopurinol (4–10 mg/kg/d, adult
maximum 300 mg/d) is indicated conditions in which there is both hyperuricemia
and hyperuricosuria, such as PRPSS or HPRT deficiency. Inhibition of xanthine dehy-
drogenase by allopurinol may lead to the accumulation and urinary excretion of
xanthine. Rarely, a secondary xanthinuria with xanthine calculi is observed in children
on long-term therapy. Allopurinol may also be the agent of choice for treating hyper-
uricosuric calcium oxalate urolithiasis if there is no concomitant evidence of hypercal-
ciuria, hyperoxaluria, or hypocitraturia.50
Pyridoxine
Pyridoxine is an important cofactor of AGT. Approximately 10% to 30% of children
with PH type I are pyridoxine sensitive (>30% reduction of urinary oxalate excretion).
In particular, patients who are homozygous for Gly170Arg or Phe152Ile mutations are
more likely to respond and have preserved renal function over time with
adequate treatment.42 In patients with suspected PH type I, treatment should be initi-
ated (2–5 mg/kg/d) and titrated upward (8–10 mg/kg/d) until a diagnosis can be made
and response assessed. Large doses of pyridoxine have been known to induce
sensory neuropathies. There is currently no evidence to suggest that pyridoxine
supplementation is beneficial in the treatment of other forms of hyperoxaluria unless
a true pyridoxine deficiency is present.REFERENCES
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